289) ytosis an obvious parameter to include in molecular pharmacological characterization |
290) rally diverse mGlu5 PAMs provides further molecular pharmacological insights and pre |
291) e remains a need to better understand the molecular pharmacological properties of mG |
292) l methods have provided valuable tools in molecular profiling and led to the identif |
293) This study aimed to establish molecular profiling and therapeutic effica |
294) Multi-modal molecular profiling data in bulk tumors or |
295) and binding of the ligands, affecting the molecular recognition process and thus the |
296) ne lipids as an integral component in the molecular recognition process. |
297) sheds important light on the long-sought molecular recognition site for DS2, refute |
298) f a minimum of 5 years, in sustained deep molecular response (DMR; molecular respons |
299) Treatment should be reintroduced if major molecular response is lost. |
300) incipal component analysis of the 93-gene molecular response to MPLA and LPS stimula |
301) important in female reproduction, but the molecular actions of androgens in female r |
302) In addition, we characterized the molecular actions of these drugs in the in |
303) Using a variety of cell and molecular biological approaches we discove |
304) opic, pathohistological, biochemical, and molecular biological findings in cell line |
305) y studies include cost-economic analysis, molecular characterisation of bacterial an |
306) here were 75 detection-method studies, 40 molecular characterisation studies, 38 stu |
307) indings support the role of the circadian molecular clock in epilepsy and suggest RE |
308) binge alcohol disrupted genes of the core molecular clock independently of elevated |
309) uctural stability of BMV under controlled molecular crowding conditions. |
310) hanochemical behavior as an effect of the molecular crowding on the entropy of the " |
311) n Huntington's disease, we saw compelling molecular data showing how cells adapt to |
312) analysis for high dimensional multi-modal molecular data to identify directly interp |
313) GABAA receptor α-subunit is the dominant molecular determinant of drug selectivity. |
314) GABAA receptor α-subunit is the dominant molecular determinant of drug selectivity. |
315) estimated 90% of CHD cases, but so far, a molecular diagnosis remains unsolved in up |
316) Mendelian genomic analyses, a presumptive molecular diagnosis was made in 13/27 (48% |
317) maging (MSI) enables the visualization of molecular distributions on complex surface |
318) ore been expanded to the 3D realm whereby molecular distributions within a 3D sample |
319) Molecular docking, western blotting, flow- |
320) argets of DHA, and these were verified by molecular docking, qRT-PCR, and Western bl |
321) ess, the structural translation of ligand molecular efficacy into G protein activati |
add keyword